Results The study included 175 patients (132 women mean age, 49.3 years mean BMI, 41.3 ) in the analysis at 3 months and 102 patients at 6 months. Secondary end points were the proportion of patients achieving weight loss of 5% or more, 10% or more, 15% or more, and 20% or more after 3 and 6 months and the percentage of weight loss for patients with or without type 2 diabetes after 3 and 6 months. Main Outcomes and Measures The primary end point was the percentage of weight loss. Patients with a history of bariatric procedures, taking other antiobesity medications, and with an active malignant neoplasm were excluded.Įxposures Weekly 1.7-mg or 2.4-mg semaglutide subcutaneous injections for 3 to 6 months. A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more. Objective To study weight loss outcomes associated with semaglutide treatment at doses used in randomized clinical trials for patients with overweight or obesity.ĭesign, Setting, and Participants This cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months. Importance No retrospective cohort study has assessed the effectiveness of semaglutide at doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg). Anti-obesity medications should get the respect and insurance coverage they deserve. Primary prevention should be the goal of all physicians, policy-makers and public health advocates. These medications can reverse chronic diseases, but we have an odd bias against preventive medicine, even when it has been proven to work. Instead of seeing these drugs as the true game-changers they are, lack of coverage has patients turning to underground networks on social media with many scams, terrible medical information and frank fraudulent advertising. Thousands of patients are thrilled with their new quality of life after they shed unhealthy weight. This, despite the findings that after starting the GLP1 and GIP combo injections, patients can decrease or eliminate diabetes medications, c-pap machines, anti-hypertensives and improve cardiovascular outcomes. Many commercial insurance plans, Medicare and Medicaid will not cover weight loss medication or have co-pays that make it unaffordable. ![]() We finally have a new medication that is effective and "turns-off" food obsessions, yet even in this study a number of patients could not afford to continue the medication. Lifestyle changes, diets and weight loss drugs have not curbed the rising prevalence. Obesity, the "mother of all diseases", is an epidemic in the US. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience. ![]() ![]() Challenges in Clinical Electrocardiography.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |